EMEA-002401-PIP01-18

Key facts

Active substance
Bemarituzumab
Therapeutic area
Oncology
Decision number
P/0241/2019
PIP number
EMEA-002401-PIP01-18
Pharmaceutical form(s)
Solution for injection
Condition(s) / indication(s)
Treatment of gastric and gastro-oesophageal junction cancer
Route(s) of administration
Intravenous use
Contact for public enquiries
Five Prime Therapeutics, Inc.

Tel. +001 415 365 5600
E-mail: Carmen.Ladner@fiveprime.com

Decision type
W: decision granting a waiver in all age groups for all conditions/indications

Decision

How useful was this page?

Add your rating